Philip Nickson
Fortuna: 1 M $ al 31/05/2026
Fortuna: 1 M $ al 31/05/2026
Philip Nickson is currently Chief Business & Legal Officer at Monte Rosa Therapeutics, Inc. since 2024.
Previously, Dr. Nickson was Vice President-Intellectual Property at Momenta Pharmaceuticals, Inc. from 2012 to 2021.
Education includes a doctorate from The University of Manchester and a graduate degree from Suffolk University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 09/04/2026 | 55.000 ( 0,07 % ) | 1 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Consejero General | 01/03/2021 |
| Empresas | Cargo | Fin |
|---|---|---|
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/03/2021 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that discovers and develops novel biologic therapies for the treatment of rare immune-mediated diseases | Health Technology |
The University of Manchester
The University of Manchester Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Suffolk University
Suffolk University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.